| | |

Tag search: "Novartis"

Promoting health through the life course

WHO pressures Big Pharma to donate more drugs for tropical diseases

The World Health Organization is urging pharma companies to help combat neglected tropical diseases via increased drugs donations. WHO said that while companies like Novartis and GlaxoSmithKline are major donors, further industry assistance is needed. ‘There is no group of diseases that is so intimately linked to poverty. The medicines exist but they are too expensive and neither do the people have the money to be able to pay’

April 24, 2017
In-Pharma Technologist

Non communicable diseases

T-cell cancer therapy holds promise, longer-term results await

A novel cell treatment that saved the life of 9-year-old Austin Schuetz was given the green light by U.S. regulatory advisers and doctors hope it can save the lives of more children with the most common type of childhood cancer. An advisory committee to the U.S. Food and Drug Administration voted unanimously to recommend approval of Novartis AG’s tisagenlecleucel for treating B-cell acute lymphoblastic leukaemia in children and young adults who relapsed or failed chemotherapy

July 13, 2017
Reuters
July 12, 2017
Reuters

Government to improve treatment of non-communicable diseases

One in every four adults in Uganda suffers from a non-communicable disease, according to a survey. With the increasing rate of NCDs in the country, the government has signed a deal with Novartis Access to increase patients’ access to treatment. The permanent secretary ministry of health, Dr. Diana Atwine said the first set of drugs includes valsartan, amlodipine for treatment of hypertension and heart failure, vildagliptin for diabetes and amoxicillin dispersible tablets for treatment of respiratory infections

July 10, 2017
New Vision

Novartis heart drug success opens up new care option

A Novartis anti-inflammatory drug cut cardiovascular risk for heart attack survivors in a pivotal trial, potentially changing ideas about treatment. Canakinumab, already approved as Ilaris for rare autoimmune conditions, was also found to reduce further heart attacks or strokes, when used with current therapies, the drugmaker said. The drug targets inflammatory atherosclerosis, where inflammation aggravates risks posed by clogged arteries

June 22, 2017
Reuters

Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment

Novartis, set to beat Kite Pharma to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once. The two therapies are vying to become the first blockbusters in an emerging field known as CAR-T, in which a patient’s immune cells are extracted and genetically modified to hunt and kill cancer before being returned to the body. Novartis may link the price of its treatment to results in each patient, according to global head of drug development Vas Narasimhan. It’s also using stem cell transplants -- which cost as much as $800,000 apiece -- as a yardstick

June 8, 2017
Bloomberg

Novartis Looks to World's Rich to Meet Need in Chronic Ailments

Novartis is in talks with banks to create a fund for investors interested in opportunities that have a social impact, Harald Nusser said in an interview. A $1bn fund started by the Abrajal Group, the Dubai-based private equity firm, is a potential model he said

March 30, 2017
Bloomberg

Health systems

Novartis sued by bird flu guinea pig

In 2007, Novartis engaged a company based in Germany and Poland to test a vaccine. This company did so in a clinic in the Polish city of Grudziadz. The subjects – homeless and poor people – were reportedly paid around CHF2 ($2) to be tested on what they thought was a vaccine for normal flu. Although no deaths have been directly proved as a result of the trial, the director of a homeless centre in Grudziadz told a Polish paper that in 2007 there were 21 deaths in the centre, compared with the average of about eight. Now, one of the subjects, Grzegorz S., has launched a civil suit against Novartis

July 13, 2017
Swiss Info
July 14, 2017
The Local

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

The U.S Supreme Court decision to speed access to copycat biologics drugs was expected but has an "immediate impact", Sanofi Chief Executive said. The justices, in a 9-0 ruling, overturned a lower court`s decision that had prevented Novartis from selling its copycat version of Amgen’s Neupogen until six months after the U.S Food and drug administration approved it. The decision has major implications for the pharmaceutical industry because it will dictate how long brand-name makers of biological drugs can keep near-copies, named biosimilars, off the market

June 16, 2017
Reuters

Google bets on European biotech drugs, backs new fund

Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi. The move shows Google casting an increasingly wide net as it pumps cash into global medical research, seeding what it believes will become a core long-term healthcare business

June 15, 2017
Reuters

Supreme Court speeds copycat biologic drugs to market

The US Supreme Court has cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies, the justices, in a 9-0 ruling, overturned a lower court decision that had prevented Swiss pharmaceutical company Novartis AG from selling its copycat version of California-based Amgen Inc`s Neupogen until six months after the U.S. Food and Drug Administration approved it

June 12, 2017
Reuters

South Korea to fine Novartis unit over unfair drug promotions

South Korean antitrust regulator said it would fine Novartis and its local unit 500 million won ($444,089) for alleged unfair promotions, in another setback for the Swiss drug maker that was fined earlier this year over kickbacks to doctors. The Korea Fair Trade Commission added that it would file a complaint against the company with prosecutors. It said that Novartis Korea had spent 7.6 billion won to fund overseas trips by medical practitioners to attend academic conferences from 2011 to 2016. Novartis Korea selected recipients for the funding based on their prescription of the company`s drugs, or anticipated prescriptions of the drugs, the regulator said

June 8, 2017
Reuters

Drug makers are bracing for Trump’s proposals to tackle U.S. prices

Two top pharmaceutical CEOs say they expect Trump, a frequent critic of industry pricing practices, to take steps to address high US drug costs, Novartis CEO Joe Jimenez and Allergan CEO Brent Saunders say they anticipate proposals from the Trump administration within the next few weeks to the next few months

May 31, 2017
Bloomberg

Moving beyond malaria – the FT asks Novartis’s Joe Jimenez three questions

Joe Jimenez, head of Novartis which provides the leading anti-malarial treatment Coartem, is asked three questions about the future for drug pricing by the Financial Times’ Andrew Jack

May 28, 2017
Financial Times

Health ministry, Novartis sign accord

Pakistan’s Ministry of Health signed an MoU agreement with Novartis Access to provide a basket of high-quality medicines in the public sector targeting four key non-communicable diseases – cardiovascular diseases, diabetes, respiratory illnesses and breast cancer. The agreement will help the most deserving to gain access to high-quality treatment at low cost to lessen the impact of chronic diseases in this developing nation

May 12, 2017
The Nation, Express Tribune

South Korea fines Novartis over kickbacks, suspends sales of some drugs

South Korea has decided to fine Novartis over paying kickbacks to doctors in exchange for recommending the company’s drugs. The government said it has levied a fine on 30 drug items and banned sales of 12 variations of 3 drug types, including Alzheimer drug Exelon, for three months

March 2, 2017
Reuters